Artiva Biotherapeutics (ARTV) Shares Outstanding (Weighted Average) (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Shares Outstanding (Weighted Average) data on file, last reported at $24.7 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $24.7 million, up 1.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.7 million (up 1.38% YoY), and the FY2025 annual result was $24.4 million, up 117.11% from the prior year.
• Shares Outstanding (Weighted Average) rose to $24.7 million in Q1 2026 per ARTV's latest filing, from $24.4 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $24.7 million in Q1 2026 and troughed at $800541.0 in Q3 2023.
• A 4-year average of $12.0 million and a median of $9.1 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) grew 1.2% in 2024, then surged 2906.08% in 2025.
• A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $802747.0 in 2023, then surged by 1302.54% to $11.3 million in 2024, then jumped by 117.11% to $24.4 million in 2025, then grew by 0.96% to $24.7 million in 2026.
• Business Quant data shows ARTV's Shares Outstanding (Weighted Average) at $24.7 million in Q1 2026, $24.4 million in Q4 2025, and $24.4 million in Q3 2025.